Array BioPharma Inc.

11.09+0.0800+0.73%Vol 1.90M1Y Perf -31.78%
Jul 1st, 2022 16:00 DELAYED
BID10.91 ASK11.42
Open11.00 Previous Close11.01
Pre-Market- After-Market10.91
 - -  -0.18 -1.62%
Target Price
14.89 
Analyst Rating
Moderate Buy 2.40
Potential %
34.27 
Finscreener Ranking
+     37.92
Insiders Trans % 3/6/12 mo.
-100/-100/-33 
Value Ranking
+     36.22
Insiders Value % 3/6/12 mo.
-100/-100/16 
Growth Ranking
+     29.29
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-1 
Income Ranking
 —    -
Price Range Ratio 52W %
25.40 
Earnings Rating
Strong Sell
Market Cap1.67B 
Earnings Date
10th Aug 2022
Alpha-0.06 Standard Deviation0.27
Beta2.16 

Today's Price Range

10.8311.51

52W Range

5.4527.67

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-
1 Month
-
3 Months
-1.86%
6 Months
-29.32%
1 Year
-31.78%
3 Years
-76.15%
5 Years
32.50%
10 Years
216.86%

TickerPriceChg.Chg.%
ARRY11.090.08000.73
AAPL138.932.21001.62
GOOG2 181.62-5.8300-0.27
MSFT259.582.75001.07
XOM87.551.91002.23
WFC39.920.75001.91
JNJ179.522.01001.13
FB196.640.99000.51
GE63.54-0.1300-0.20
JPM114.051.44001.28
Financial StrengthValueIndustryS&P 500US Markets
1.10
1.90
0.67
7.62
-2.00
Leverage Ratio -258.20
ProfitabilityValueIndustryS&P 500US Markets
7.00
-7.60
-2.90
-58.70
-8.29
RevenueValueIndustryS&P 500US Markets
907.97M
6.05
15.84
25.13
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.09-0.0544.44
Q04 2021--0.07-
Q03 2021-0.05-0.08-60.00
Q02 20210.020.04100.00
Q01 20210.160.13-18.75
Q04 20200.060.0716.67
Q03 2020-0.07-
Q03 2019-0.21-0.1719.05
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.02-81.82Negative
9/2022 QR0.11-38.89Negative
12/2022 FY0.24-52.94Negative
12/2023 FY0.81-26.36Negative
Next Report Date10th Aug 2022
Estimated EPS Next Report0.03
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume1.90M
Shares Outstanding150.18K
Shares Float149.55M
Trades Count19.84K
Dollar Volume21.02M
Avg. Volume1.47M
Avg. Weekly Volume1.09M
Avg. Monthly Volume0
Avg. Quarterly Volume3.30M

Array BioPharma Inc. (NASDAQ: ARRY) stock closed at 11.3 per share at the end of the most recent trading day (a 3.59% change compared to the prior day closing price) with a volume of 4.04M shares and market capitalization of 1.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs people. Array BioPharma Inc. CEO is .

The one-year performance of Array BioPharma Inc. stock is -31.78%, while year-to-date (YTD) performance is -29.32%. ARRY stock has a five-year performance of 32.5%. Its 52-week range is between 5.445 and 27.6708, which gives ARRY stock a 52-week price range ratio of 25.40%

Array BioPharma Inc. currently has a PE ratio of -16.30, a price-to-book (PB) ratio of 17.19, a price-to-sale (PS) ratio of 2.06, a price to cashflow ratio of 60.70, a PEG ratio of 2.32, a ROA of -9.21%, a ROC of -12.49% and a ROE of -494.49%. The company’s profit margin is -8.29%, its EBITDA margin is -2.90%, and its revenue ttm is $907.97 Million , which makes it $6.05 revenue per share.

Of the last four earnings reports from Array BioPharma Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.03 for the next earnings report. Array BioPharma Inc.’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for Array BioPharma Inc. is Moderate Buy (2.4), with a target price of $14.89, which is +34.27% compared to the current price. The earnings rating for Array BioPharma Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Array BioPharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Array BioPharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 62.62, ATR14 : 1.03, CCI20 : 1.69, Chaikin Money Flow : 0.14, MACD : -0.24, Money Flow Index : 55.84, ROC : 10.78, RSI : 0.36, STOCH (14,3) : 35.59, STOCH RSI : 0.00, UO : 48.37, Williams %R : -64.41), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Array BioPharma Inc. in the last 12-months were: Erica Brinker (Sold 3 975 shares of value $49 811 ), Gerrard Schmid (Buy at a value of $193 882), Tyson Hottinger (Sold 6 442 shares of value $90 169 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (40.00 %)
3 (30.00 %)
3 (27.27 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (9.09 %)
Hold
5 (50.00 %)
6 (60.00 %)
6 (54.55 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (10.00 %)
1 (10.00 %)
1 (9.09 %)
Summary RatingModerate Buy
2.40
Hold
2.60
Moderate Buy
2.55

Array BioPharma Inc.

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its clinical stage drugs include Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292 and LOXO-195 among others. The company has geographical presence in North America, Europe and Asia Pacific.

CEO:

Telephone: +1 303 381-6600

Address: 3200 Walnut Street, Boulder 80301, CO, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

Bearish Bullish

57%43%

TipRanks News for ARRY

Wed, 29 Jun 2022 16:32 GMT Array Technologies (ARRY) Receives a Hold from Morgan Stanley

- TipRanks. All rights reserved.

News

Stocktwits